One way to guarantee the rise of antibiotic resistance is to treat bacterial infections with the same antibiotics over and over again. This accelerates the emergence of resistant phenotypes, and this is exactly what is happening. Findings of a recent global study of antibiotic resistance by Biopharm Reports show that just ten antibiotic classes are being used to treat 86% of all infections, while only five classes are being used to treat 60% of infections. These practices have huge implications for the looming threat of antibiotic resistance globally, and define what might be described as the ‘perfect storm’ in this field.
But while these statistics are alarming, global strategies to tackle antibiotic resistance are advancing too, providing opportunities to slow the advance of this threat. The last few years have seen a significant jump in the number of new pipeline antibiotics and targeting strategies, as well as improvements in and increasing use of diagnostics methods, alongside more informed drug prescribing practices, integrated approaches and the use of surveillance data on local infections, all of which offer opportunities to slow the advance of antibiotic resistance.
These are some of the conclusion from a new report on antibiotic resistance, involving the participation of 650 clinicians and researchers in 80 countries. The findings of this study provide a comprehensive overview of current and evolving practices, developments and strategies and their importance to the better management of antibiotic resistance.
The report is available to buy from MarketReports.com.